Skip to content
The Policy VaultThe Policy Vault

Jakafi (ruxolitinib tablets) — Cigna

Acute Lymphoblastic Leukemia

Initial criteria

  • Patient age < 21 years
  • The mutation/pathway is Janus Associated Kinase (JAK)-related

Approval duration

1 year